Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

University of Colorado, Denver · NCT06414096

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 19–37 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
60
US sites recruiting
1
Study start
October 1, 2024
Record last updated
October 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Hypothesis: The investigators hypothesize that pulsatile FSH intravenous administration to women with obesity will correct the Reprometabolic Syndrome (RMS) luteal deficiency phenotype.

Specific Aim: To test the hypothesis that pulsatile IV administration of FSH will rescue the impaired folliculogenesis and relative hypogonadotropic hypogonadism, characteristic of obesity. This study will also try to rescue the diminished ovarian reserve phenotype in the same fashion. The investigators will accomplish this by administering a cycle of pulsatile FSH to women with obesity and comparing their hormone output to a cycle using conventional, daily FSH injection at the identical daily dose. The primary outcome will be luteal phase progesterone excretion.

Being studied: Follicle Stimulating Hormone

Conditions: Infertility; Obesity; Diminished Ovarian Reserve (DOR); Diminished Ovarian Reserve

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria (obseity):

  • • BMI between 30 kg/m2 and 40 kg/m
  • Weight stability, i.e. no continued weight loss of >1lb per week for a minimum of 4 weeks prior to enrollment
  • Normal thyroid stimulating hormone (TSH) and prolactin
  • Anti-Mullerian Hormone (AMH) > 1 ng/ml or \< 8 ng/mL
  • Willingness to postpone conception for the first study cycle
  • Involuntary inability to conceive for at least 6 months
  • No clinical diagnosis of polycystic ovarian syndrome (PCOS)
  • Documentation of ovulation with luteal progesterone >6 ng/ml or positive ovulation predictor home testing
  • Regular menstrual cycles 25-40 days in length
  • Male partner (or sperm donor) with adequate sperm (>14 million sperm per ml)
  • Hysterosalpingogram or saline infusion sonography demonstrating at least one patent Fallopian tube and a normal uterine cavity
  • Serum total and free testosterone within the 95% CIearance for women with obesity previously studied in our laboratory.
  • Acceptance of the indwelling catheter and willingness to take part in the study

Inclusion criteria (DOR):

  • BMI less than 30 kg/m2
  • Normal TSH and prolactin
  • Regular menstrual cycles 25-40 days in length
  • Male partner (or sperm donor) with adequate sperm (>14M sperm per ml)
  • Hysterosalpingogram or saline infusion sonography demonstrating at least one patent Fallopian tube and a normal uterine cavity
  • Anti-Mullerian Hormone (AMH) \< 1.0 ng/ml
  • Antral follicle count 8 or less
  • Willingness to postpone conception for the first study cycle
  • at least 2 prior canceled cycles for lack of response at maximum dose
  • Involuntary inability to conceive for at least 6 months
  • Acceptance of the indwelling catheter and willingness to take part in the study

Recruiting US locations

  • University of Colorado Anschutz Medical Campus

    Aurora, CO 80045

    Site contact: Asma Giornazi, MS · 303-724-5276 · asma.giornazi@cuanschutz.edu

Study contacts (from the official record)

  • Asma Giornazi, MS · 303-7245276 · asma.giornazi@cuanschutz.edu
  • Carrie Hsu · 303-724-5276 · carrie.hsu@cuanschutz.edu
All weight loss studies in Colorado →
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome (NCT06414096) | Bored Studies